Alert: New Earnings Report (8/6/24)-Halozyme Therapeutics Inc (NASDAQ: HALO).
For its second fiscal quarter (ending June 30), Halozyme Therapeutics Inc (NASDAQ: HALO) has reported a 28% increase in E.P.S. from $0.57 a year ago to $0.73 in the current quarter. However, this performance was […]